ArticleEuropean journal of nuclear medicine and molecular imaging2020
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Comparison of [European radiology · 2026Pooled it
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Multicenter evaluation of commercial AI for [Annals of nuclear medicine · 2026Article
- Prognostic value of TMTV and Dmax calculated fromEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Applications and research progress of PET/CT in dynamic monitoring of immunotherapy in melanoma.Journal of translational medicine · 2026Review
- Tumor-Induced Rewiring of Splenic Niches: from Immune Organ to Cancer Accomplice.International journal of biological sciences · 2026Review
- The Prognostic Value of Biomarkers Identified by [Diagnostics (Basel, Switzerland) · 2025Article
- [Molecular imaging and biology · 2025Article
- Predictive value of [European radiology · 2025Article
- Prognostic value of FDG-PET/CT findings in mucosal melanoma of the head and neck treated with carbon ion radiotherapy.Annals of nuclear medicine · 2025Article
- Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.Scientific reports · 2025Article
- Metabolic parameters on baseline and early [EJNMMI research · 2025Article
- Novel Clinical PET Tracers in the Pipeline for Melanoma.Current oncology reports · 2025Review
- 3'-deoxy-3'-EJNMMI research · 2025Article
- Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survival.Translational lung cancer research · 2024Article
- Precision Oncology in Melanoma: Changing Practices.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.Translational lung cancer research · 2024Article
- Review on radiomic analysis inCancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs).
methodsIn this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n = 24) or Cut-M (n = 32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) tumoral tissues: SUVmax, SUVmean, TMTV (total metabolic tumor volume), and TLG (total lesion glycolysis) and (ii) lymphoid tissues: BLR (bone marrow-to-liver SUVmax ratio) and SLR (spleen-to-liver SUVmax ratio). Association with survival and response was evaluated using Cox prediction models, Student's t tests, and Spearman's correlation respectively. p < 0.05 was considered significant.
resultsMajority of ICIs were anti-PD1 (92.9%, n = 52/56). All 18F-FDG-PET/CT were positive. Overall (Muc-M to Cut-M), ORR was 33%:42%, DCR was 56%:69%, median follow-up was 25.0:28.9 months, median PFS was 4.7:10.7 months, and median OS was 23.9:28.3 months. In Muc-M, increased tumor SUVmax was associated with shorter OS while it was not correlated with PFS, ORR, or DCR. In Cut-M, increased TMTV and increased BLR were independently associated with shorter OS, shorter PFS, and lower response (ORR, DCR).
conclusionWhile all Muc-M and Cut-M were FDG avid, prognostic imaging biomarkers differed. For Muc-M patients treated with ICI, the only prognostic imaging biomarker was a high baseline maximal glycolytic activity (SUVmax), whereas for Cut-M patients, baseline metabolic tumor burden or bone marrow metabolism was negatively correlated to ICI response duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.